Embryonic transcription factor SOX9 drives breast cancer endocrine resistance

The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation is the development of endocrine resistance especially in the setting of metasta...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Proc Natl Acad Sci U S A
Autori principali: Jeselsohn, Rinath, Cornwell, MacIntosh, Pun, Matthew, Buchwalter, Gilles, Nguyen, Mai, Bango, Clyde, Huang, Ying, Kuang, Yanan, Paweletz, Cloud, Fu, Xiaoyong, Nardone, Agostina, De Angelis, Carmine, Detre, Simone, Dodson, Andrew, Mohammed, Hisham, Carroll, Jason S., Bowden, Michaela, Rao, Prakash, Long, Henry W., Li, Fugen, Dowsett, Mitchell, Schiff, Rachel, Brown, Myles
Natura: Artigo
Lingua:Inglês
Pubblicazione: National Academy of Sciences 2017
Soggetti:
PNAS Plus
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5465894/
https://ncbi.nlm.nih.gov/pubmed/28507152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1620993114
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi